<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2538">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073850</url>
  </required_header>
  <id_info>
    <org_study_id>KUGH12078-001</org_study_id>
    <nct_id>NCT03073850</nct_id>
  </id_info>
  <brief_title>Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation</brief_title>
  <acronym>ATEMS-AF</acronym>
  <official_title>Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the best strategy for long-term stroke prevention
      in patients who have sinus rhythm after a successful catheter ablation for atrial
      fibrillation (AF) and who are at risk of thromboembolic events (CHA2DS2-VASc score â‰¥2). The
      investigators are going to compare antiplatelet therapy to oral anticoagulation (OAC) with
      different doses of edoxaban (30mg and 60mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that the strategy of OAC will be superior to antiplatelet
      therapy, but low dose edoxaban (30mg) will be non-inferior to standard dose edoxaban (60mg)
      for reducing the risk of stroke or systemic embolism in patients who underwent successful AF
      ablation. Although AF ablation is an effective therapy for reducing and/or eliminating the
      burden of AF, there may continue to be a risk of late recurrence or asymptomatic recurrence
      of atrial tachyarrhythmias. Until now, the guideline has recommended the continuation of OAC
      in patients who are at risk of stroke or systemic embolism based on the CHA2DS2-VASc score,
      even though they have maintained sinus rhythm. The annual rate of stroke, however, is still
      lower compared to that predicted by the scoring system, because AF ablation reduced the AF
      burden by 86% and the remaining episodes were significantly shorter in duration (median 6
      minutes) than those pre-ablation reported by the previous study. Based on recent studies
      which demonstrated that both standard-dose and low-dose non-vitamin K OACs (NOAC) performed
      equally well with regard to the stroke prevention in patients with AF, low dose NOACs may
      also be sufficient for stroke prevention of briefly lasting AF episodes after successful AF
      ablation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Anticipated">August 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom rate of stroke or systemic embolism during 2 years after successful AF ablation procedure</measure>
    <time_frame>2 year</time_frame>
    <description>Check stroke or systemic embolism through neurologic examination or imaging studies</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Lone antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose OAC therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>edoxaban 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose OAC therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>edoxaban 60mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet</intervention_name>
    <description>ASA or clopidogrel</description>
    <arm_group_label>Lone antiplatelet therapy</arm_group_label>
    <other_name>Use of Antiplatet agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulants</intervention_name>
    <description>Edoxaban</description>
    <arm_group_label>Low dose OAC therapy</arm_group_label>
    <arm_group_label>Standard dose OAC therapy</arm_group_label>
    <other_name>Use of anticoagulants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients without evidence of any clinically apparent arrhythmia recurrence during at
             least six months after last catheter ablation of AF.

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Patients who do not meet all of the above listed inclusion criteria.

          -  Patients with significant valvular heart disease or mechanical valve.

          -  Patients with hypertrophic cardiomyopathy.

          -  Patients with chronic renal impairment with creatinine clearance rate of &lt; 50 mg/dl.

          -  Patients with contraindication to long-term OAC.

          -  Patients who had a stroke within one year prior to enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Euy Lim, Dr.</last_name>
    <phone>82-2-2626-1046</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemin Shim, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Euy Lim, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eue-Keun Choi, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui-Nam Pak, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>February 2, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hong Euy Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
